With only six months to go before its end, the PneumoNP consortium gathered once more for their penultimate progress meeting on June 20-21, 2017 hosted in the beautiful city of Maastricht by project partner PathoFinder.
During the 1.5-day meeting, the consortium partners discussed the course for the last six months of the project’s duration. The primary goal to bear in mind: to reach the maximum outcome of the project!
PneumoNP focuses on the development of a theragnostic system for the treatment of resistant Gram-negative bacterial infections in the lungs. For the treatment, a nanotherapeutic based inhalable antibiotic will be developed composed of a nanocarrier combined with an antimicrobial peptide. Based on the concentration of the drug in the lungs, level of toxicity side effects and the therapeutic efficacy of the nanoformulations used in pilot tests, the setup of the in vivo tests at Erasmus MC was fixed at the meeting.
PneumoNP’s consortium at its meeting in June 2017 in PathoFinder’s facilities
A visit to PathoFinder’s facilities rounded up the meeting. PathoFinder contributes to PneumoNP by improving the usage of antibiotics with the development of a diagnostic kit. The kit allows to identify antibiotic resistant strains of bacteria from a unique sample.
Right before its end, PneumoNP is happy to announce its 2nd workshop. It will take place within the scope of the Molecular Imaging Workshop (MIW2017) organised by PneumoNP partner CIC biomaGUNE on November 20-23, 2017 in San Sebastian, Spain. The MIW2017 offers the opportunity to discuss molecular imaging applications to neurosciences and oncology. PneumoNP will take part with a half-day workshop on November 23, 2017. Several partners from the project will present their work in PneumoNP in relation to imaging.
Iraida Loinaz, coordinator of the PneunoNP project, attends the EuroNanoForum 2017 conference.
EuroNanoForum 2017 is an international event that focus on how nano and materials technologies can strengthen competitiveness across all European industries. The event takes place in Malta from 21th and 23th June 2017.
Nanotechnology is expected to gain importance in the near future in many industries. For example, nanomedicine could solve numerous healthcare challenges especially in the field of drug-delivery. However, from the pharmaceutical point of view, there is insufficient clinical data that allows the assessment of the role of nanotechnology in the potential of these products.
It is time to push those promising developments to the clinical stage. Iraida Loinaz’s talk will show real examples on how is possible to translate a lab scale protocol, into a robust GMP manufacturing process, and those key aspects to take into account to reduce the time of development.
Iraida Loinaz, coordinator of PneunoNP project, is the Health business development Manager of IK4-Cidetec. In the last years Dr. Loinaz’s group has been specialized in translational research. They are establishing a pilot plant operating under GMP for the production of nanopharmaceuticals.
“It is my first time attending EuroNanoForum,” Dr Loinaz said. “I really look forward to meeting main stakeholders in the field of nanotechnologies for health and share our experiences in the field.”
Find all the necessary information related to the event on: www.eccmid.org.
To slow down the rise of non-curable infections, a Dutch company developed a diagnostic kit to identify strains of antibiotic-resistant bacteria.
The World Health Organization (WHO) warns citizens for several years now: many antibiotics are becoming useless to heal bacterial infections. Indeed, bacteria develop new defence mechanisms to resist the action of antibiotics. By accurate detection of these resistance mechanisms, prescription of useless antibiotics can be avoided. Instead, an appropriate antibiotic treatment can be prescribed to cure the patient.
A precise diagnosis contributes also to avoid the spread of resistant bacteria and the rise of new resistance mechanisms. Supposing all infections were treated with personalized antibiotic treatments, bacteria would have less room to evolve or to spread.
To tackle these challenges, the Dutch company PathoFinder strives to provide an on-time delivery and dependable diagnostic system. The kit will allows to identifying antibiotic resistant strains of bacteria from a unique sample. This new kit addresses the need of hospitals, where time and precision are valuable.
The kit, a PCR multiplex, can identify over 25 of the most important resistance gene families, namely carbapenemases, extended-spectrum beta-lactamases (ESBL), plasmid-mediated cephalosporinases (pAmpC) and plasmid-mediated colistin resistance genes.
PathoFinder, accredited of the ISO 13485, benefits from a long experience in medical devices’ design. This time, the team innovates with a multiplex that runs on standard laboratory equipments. About 3 years and a half were needed for the multiplex to be conceived. Later in 2017, the multiplex will enter clinical validation. It will need a few more official certifications before entering the market.
The company PathoFinder was supported by a European consortium of academic and private research groups. Indeed, the Dutch company participates to the PneumoNP project. The rapid development of the multiplex would not be possible without the contribution of their partners. Together they engage against the rise of antibiotic resistance. In this framework, PathoFinder contributes by improving usage of antibiotics with the development of the diagnostic kit.
The second edition of the Molecular Imaging Workshop 2017 (MIW2017) will be held from 20th to 23rd November 2017 in San Sebastian, Spain. Abstract submission is open until the 31st August 2017.
Academic and industrial researchers are welcome to join the workshop. For instance an industrial forum is organized to exchange ideas and network. People can also submit abstracts to participate to the poster session.
Organized by CIC biomaGUNE, the workshop will cover topics related to molecular imaging. The MIW2017 is the opportunity to discuss molecular imaging applications to neurosciences and oncology. Do not miss the sessions dedicated to cardiovascular application, infection tracking and pneumology.
The PneumoNP project will also attend the event. Attendees will be updated of the latest results of the project.
Several invited speakers are already announced. Jesús Ruíz Cabello from the Complutense University of Madrid, Spain, will give a lecture on the “characterization of metabolic reprogramming in pulmonary hypertension”. Jason Holland will come from Zurich to discuss “PET radiotracers for imaging oncogenic signaling pathways”.
The full list of invited speakers is available on the MIW2017 website.
You can already submit your abstract for the MIW2017 and so until the 31st August 2017. All abstracts must be related to one of the following categories:
Infectious diseases and metabolism
Imaging technology, methodology and data analysis
Pulmonology and respiratory
Changes in the application are accepted until the submission deadline. So, do not wait and submit your abstract on the MIW2017 website.
PneumoNP partners will attend ECCMID 2017 in Vienna, Austria, from 22-25th April 2017.
ECCMID is a major event for experts of infectious diseases and clinical microbiology. A wide range of these topics will be discussed during symposia and poster sessions.
Several PneumoNP partners attend ECCMID 2017. They will present and discuss the latest results of the PneumoNP projects.
PathoFinder will have a company booth. They will display next generation multiplex PCR diagnostics kits for infectious diseases. One is under development in the framework of the PneumoNP project.
On Sunday 23rd, Alessandro Pini, from the company SetLance, will give a presentation during the session: Host-pathogen interactions provide opportunities for novel therapy. The session takes place in hall H from 11:30 to 12:30. His presentation will covers “the peptide SET-M33 as novel agent to neutralize and remove LPS in patients with sepsis”.
Meet us also during the session: New drugs against Gram-negatives. The session takes place in hall K on Monday 24th from 09:00 to 11:00. Chiara Falciani, from the company SetLance, will give a presentation entitled “An antimicrobial peptide to face multidrug-resistance emergency: synergies and mechanism of action underpinning efficacy”.
Find all the necessary information related to the event on: www.eccmid.org. The full programme is available on the website ECCMIDLive.